Clinical trial
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising…
NCT00148772 · Endeavor Health, Other · Completed
Key facts
| NCT number | NCT00148772 |
|---|---|
| Title | Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy |
| Official title | Phase II Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising PSA on Hormone Therapy |
| Lead sponsor | Endeavor Health, Other |
| Collaborators | Genentech, Inc. Industry Northwestern University |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib (Tarceva) |
| Enrollment | 29 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 28, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: